| Psychology and Behavioral Sciences | Lifetime | 762 | NL 25 | 99.69 |
| Clinical Psychology | Lifetime | 261 | NL 8 | 99.70 |
| Epidemiology | Lifetime | 432 | NL 13 | 99.46 |
| Clinical Pharmacology | Lifetime | 223 | NL 9 | 99.07 |
| Public, Environmental and Occupational Health | Lifetime | 700 | NL 25 | 99.02 |
| Toxicology | Lifetime | 33 | NL 3 | 98.30 |
| Psychiatry and Mental health | Lifetime | 383 | NL 10 | 98.77 |
| Cellular and Molecular Neuroscience | Lifetime | 622 | NL 6 | 97.42 |
| Clinical Pharmacology | 2021-2025 | 198 | NL 6 | 93.00 |
| Public, Environmental and Occupational Health | 2021-2025 | 690 | NL 16 | 93.30 |
| Clinical Psychology | 2021-2025 | 781 | NL 26 | 91.61 |
| Epidemiology | 2021-2025 | 955 | NL 25 | 90.04 |
| Toxicology | 2021-2025 | 35 | NL 3 | 88.75 |
| Clinical Neurology | 2021-2025 | 529 | NL 14 | 78.96 |
| Substance Abuse Treatment and Outcomes | Lifetime | 23 | NL 1 | 99.62 |
| Forensic Toxicology and Drug Analysis | Lifetime | 14 | NL 1 | 99.45 |
| Cannabis and Cannabinoid Research | Lifetime | 36 | NL 1 | 99.41 |
| Opioid Use Disorder Treatment | Lifetime | 31 | NL 1 | 99.45 |
| Neurotransmitter Receptor Influence on Behavior | Lifetime | 109 | NL 2 | 99.39 |
| Alcohol Consumption and Health Effects | Lifetime | 130 | NL 1 | 98.58 |
| Alcoholism and Thiamine Deficiency | Lifetime | 40 | NL 3 | 98.19 |
| Attention Deficit Hyperactivity Disorder | Lifetime | 139 | NL 10 | 98.79 |
| Prenatal Substance Exposure Effects | Lifetime | 96 | NL 1 | 98.30 |
| Schizophrenia research and treatment | Lifetime | 316 | NL 10 | 98.86 |
| Psychedelics and Drug Studies | Lifetime | 55 | NL 3 | 97.66 |
| Gambling Behavior and Treatments | Lifetime | 48 | NL 2 | 98.05 |
| Personality Disorders and Psychopathology | Lifetime | 161 | NL 7 | 97.70 |
| Mental Health Treatment and Access | Lifetime | 662 | NL 23 | 96.96 |
| Obsessive-Compulsive Spectrum Disorders | Lifetime | 378 | NL 16 | 96.58 |
| Pain Management and Opioid Use | Lifetime | 420 | NL 6 | 96.15 |
| Homelessness and Social Issues | Lifetime | 976 | NL 10 | 94.90 |
| Treatment of Major Depression | Lifetime | 711 | NL 23 | 95.30 |
| Poisoning and overdose treatments | Lifetime | 617 | NL 5 | 91.83 |
| Youth Substance Use and School Attendance | Lifetime | 866 | NL 37 | 74.37 |
| Alcoholism and Thiamine Deficiency | 2021-2025 | 5 | NL 1 | 95.46 |
| Substance Abuse Treatment and Outcomes | 2021-2025 | 65 | NL 1 | 97.58 |
| Prenatal Substance Exposure Effects | 2021-2025 | 64 | NL 1 | 95.28 |
| Neurotransmitter Receptor Influence on Behavior | 2021-2025 | 93 | NL 4 | 94.92 |
| Opioid Use Disorder Treatment | 2021-2025 | 204 | NL 2 | 95.63 |
| Forensic Toxicology and Drug Analysis | 2021-2025 | 106 | NL 2 | 92.25 |
| Cannabis and Cannabinoid Research | 2021-2025 | 299 | NL 5 | 91.86 |
| Psychedelics and Drug Studies | 2021-2025 | 198 | NL 12 | 87.37 |
| Treatment of Major Depression | 2021-2025 | 415 | NL 22 | 86.44 |
| Attention Deficit Hyperactivity Disorder | 2021-2025 | 851 | NL 35 | 79.29 |
| Chemical synthesis and alkaloids | 2021-2025 | 347 | NL 9 | 77.86 |
| Poisoning and overdose treatments | 2021-2025 | 487 | NL 9 | 67.02 |
| Gambling Behavior and Treatments | 2021-2025 | 546 | NL 7 | 52.11 |
